# Management of OAB in Female Patients .

> **NCT06184334** · NA · COMPLETED · sponsor: **Elsayed Abdelhalim Elsayed** · enrollment: 300 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Solfenacin
- **DRUG:** Mirabegron
- **DRUG:** Tadalafil 5mg

## Key facts

- **NCT ID:** NCT06184334
- **Lead sponsor:** Elsayed Abdelhalim Elsayed
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-14
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06184334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06184334, "Management of OAB in Female Patients .". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06184334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*